The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy. (Q39274501)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

Thibaut Legigan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Jonathan Clarhaut

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Isabelle Tranoy-Opalinski

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Brigitte Renoux

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Mikaël Thomas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Alain Le Pape

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Stéphanie Lerondel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

Sébastien Papot

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

20 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

Angewandte Chemie International Edition

13 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

11606-11610

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

Prodrug strategies in anticancer chemotherapy

13 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Antibody-drug conjugates: targeted drug delivery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Enzyme-catalyzed activation of anticancer prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Antibody directed enzymes revive anti-cancer prodrugs concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Design of selectively activated anticancer prodrugs: elimination and cyclization strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Design of self-immolative linkers for tumour-activated prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Regulated portals of entry into the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Folate receptor-targeted drugs for cancer and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Folate-targeted therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Folate-targeted therapeutic and imaging agents for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Synthesis and activity of a folate peptide camptothecin prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Folate receptor-mediated drug targeting: from therapeutics to diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

Rotaxane-Based Propeptides: Protection and Enzymatic Release of a Bioactive Pentapeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201204935

21 January 2018

Identifiers

DOI

10.1002/ANIE.201204935

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22996951%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference